• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Redmile Group, Llc

    4/2/26 9:00:23 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last)(First)(Middle)
    900 LARKSPUR LANDING CIRCLE,
    SUITE 270

    (Street)
    LARKSPUR CALIFORNIA 94939

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    ADC Therapeutics SA [ ADCT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/31/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock03/31/2026S196,229D$3.752(3)15,470,502ISee Footnote(1)
    Common Stock03/31/2026S188,407D$3.752(3)12,957,305D(2)
    Common Stock04/01/2026S169,265D$3.799(4)15,301,237ISee Footnote(1)
    Common Stock04/01/2026S162,517D$3.799(4)12,794,788D(2)
    Common Stock04/02/2026S2,634,506D$3.279(5)12,666,731ISee Footnote(1)
    Common Stock04/02/2026S2,529,491D$3.279(5)10,265,297D(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    1. Name and Address of Reporting Person*
    Redmile Group, LLC

    (Last)(First)(Middle)
    900 LARKSPUR LANDING CIRCLE,
    SUITE 270

    (Street)
    LARKSPUR CALIFORNIA 94939

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Green Jeremy

    (Last)(First)(Middle)
    C/O REDMILE GROUP, LLC (NY OFFICE)
    45 W. 27TH STREET, FLOOR 11

    (Street)
    NEW YORK NEW YORK 10001

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    RedCo II Master Fund, L.P.

    (Last)(First)(Middle)
    C/O REDMILE GROUP, LLC
    900 LARKSPUR LANDING CIRCLE, SUITE 270

    (Street)
    LARKSPUR CALIFORNIA 94939

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including RedCo II Master Fund, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
    2. These securities are directly owned by RedCo II Master Fund, L.P.
    3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
    4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.83, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
    5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.77, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
    Remarks:
    The sales reported herein were effected within a period of less than six months from the purchases of pre-funded warrants to purchase the Issuers' Common Stock reported in the Form 4 filed by the Reporting Persons on October 28, 2025. However, the sales reported herein were effected at a price lower than the previous purchases that were reported in the Form 4 filed on October 28, 2025, such that no profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b).
    By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC04/02/2026
    /s/ Jeremy Green, Managing Member of RedCo II (GP), LLC, the General Partner of RedCo II Master Fund, L.P.04/02/2026
    /s/ Jeremy Green04/02/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ADCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADCT

    DatePrice TargetRatingAnalyst
    6/4/2026$2.00Outperform → Sector Perform
    RBC Capital Mkts
    11/8/2024$6.00Overweight
    Stephens
    5/30/2024Overweight
    Cantor Fitzgerald
    3/28/2024$11.00Buy
    Guggenheim
    8/10/2023Underweight → Neutral
    JP Morgan
    4/24/2023$7.00 → $2.00Neutral → Underperform
    BofA Securities
    12/6/2022$12.00Overweight
    CapitalOne
    11/9/2022$14.00 → $7.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $ADCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    12/13/24 9:00:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    7/3/24 8:00:13 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ADC Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded ADC Therapeutics from Outperform to Sector Perform and set a new price target of $2.00

    6/4/26 8:41:44 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on ADC Therapeutics with a new price target

    Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00

    11/8/24 7:32:36 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on ADC Therapeutics

    Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight

    5/30/24 7:26:04 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    SEC Filings

    View All

    ADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ADC Therapeutics SA (0001771910) (Filer)

    6/3/26 4:17:06 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics SA filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ADC Therapeutics SA (0001771910) (Filer)

    6/2/26 4:01:37 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ADC Therapeutics SA

    10-Q - ADC Therapeutics SA (0001771910) (Filer)

    5/4/26 4:15:10 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Leadership Updates

    Live Leadership Updates

    View All

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

    £90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi

    7/8/24 2:00:00 AM ET
    $ADCT
    $CG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

    LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th

    6/27/24 7:15:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA plus rituximab achieved statistical significance on the trial's primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with

    6/3/26 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

    LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year endFirst quarter 2026 net product revenue of $20.0 millionCash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.

    5/4/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and

    5/1/26 4:05:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Azelby Robert was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 40% to 112,805 units (SEC Form 4) to cover withholding tax

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    6/3/26 5:03:43 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Squarer Ron was granted 45,000 shares and covered exercise/tax liability with 15,196 shares, increasing direct ownership by 32% to 123,431 units (SEC Form 4) to satisfy withholding obligation

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    6/3/26 5:03:29 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sandor Victor was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 140,686 units (SEC Form 4) (tax withholding)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    6/3/26 5:03:16 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Financials

    Live finance-specific insights

    View All

    ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA plus rituximab achieved statistical significance on the trial's primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with

    6/3/26 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

    LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year endFirst quarter 2026 net product revenue of $20.0 millionCash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.

    5/4/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

    LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event,

    4/27/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:58:56 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:30:55 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care